Determination of surgeon’s absorbed dose in iodine 125 and ruthenium 106 ophthalmic plaque surgery

Laube, Thomas; Flühs, Dirk; Kessler, C; Bornfeld, Norbert

doi:10.1016/s0161-6420(99)00050-0

Cited by 22 publications

(14 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Laube et al [19] examined the radiation from iodine-125 and ruthenium-106 plaques on the fingers of ophthalmologists and concluded that there was an average exposure dose of only 2–6 mSv per procedure. They resolved that a surgeon could safely administer 200 ruthenium or/and 100 iodine plaques annually.…”

Section: Discussionmentioning

confidence: 99%

“…They resolved that a surgeon could safely administer 200 ruthenium or/and 100 iodine plaques annually. However, to account for additional exposure during patient follow-up examinations, they recommended an annual limit of 100 ruthenium plaque administrations and 50 iodine ones [7]. A 2012 study evaluated the radiation exposure to a surgeon’s hand during the administration of iodine-125 plaques in patients with uveal melanomas [5].…”

Section: Discussionmentioning

confidence: 99%

“…Iodine, ruthenium, and palladium radioisotopes are commonly utilized for treating uveal melanoma and may also be used for treating invasive squamous cell carcinoma, metastatic choroidal lesions, retinoblastoma, and some benign retinal and choroidal tumors [3, 4]. The total dose to which the surgeon is exposed depends upon the plaque type, overall radiation dose loaded in the plaque, surgical time with the active “hot” plaque, and proximity to the unshielded side of the plaque [5, 7]. The key components in radiation protection are operative duration, distance, and shielding [3].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Trends in Radiation Practices for Female Ocular Oncologists in North America: A Collaborative Study of the International Society of Ocular Oncology

et al. 2018

View full text Add to dashboard Cite

Background: The aim of this study was to determine the known radiation exposure, attitudes, and consequent risk modifications among female ocular oncologists in North America who routinely administer radioactive plaque brachytherapy treatment and are members of the International Society of Ocular Oncology. Methods: Nineteen female ocular oncologists completed an anonymous 17-question radiation exposure survey. Results: Eleven of the participants chose to routinely wear lead protection during surgery; 8 did not. Fifteen of 19 participants reported using an unloaded “nonactive” template to prepare for plaque implantation. During pregnancy, 11 of 13 participants continued to perform plaque brachytherapy. Eight of these 11 undertook measures to decrease radiation exposure self-reported as lead wear and other. The average reported anxiety regarding fertility was 2.1 (SD, 2.2) on a scale from 1 to 10. Conclusion: This study corroborates prior literature that surgeons’ exposure to radiation during plaque brachytherapy is minimal. Nonetheless, there remains some anxiety regarding exposure risk to women, due to potential effects on fertility and fetal health. We found variability in exposure monitoring, required training, and precautions during pregnancy amongst this group of surgeons. Improved education and clearer pregnancy guidelines may equip female ocular oncologists with optimal knowledge regarding risk of radiation exposure.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Trends in Radiation Practices for Female Ocular Oncologists in North America: A Collaborative Study of the International Society of Ocular Oncology

et al. 2018

View full text Add to dashboard Cite

show abstract

“…La energía media del iridio-192, de 0,38 MeV es relativamente baja y por lo tanto es aceptable en cuanto a radioprotección. Sin embargo es 10 veces mayor que la del yodo-125 y requiere 1,2 cm de plomo para reducir la exposición al 10%, lo que impide proteger los tejidos orbitarios (glándula lagrimal) y multiplica la exposición del personal sanitario respecto a la que se produce con el yodo-125 21,22 . La vida media del iridio-192, de 74,2 días, se considera corta, pero es larga si la comparamos con la media de la duración del tratamiento, en torno a 6 días, de modo que su actividad se reduce sólo en un pequeño porcentaje durante el tratamiento 18 .…”

Section: Discussionunclassified

Braquiterapia con hilos extraesclerales de iridio-192 en melanomas uveales posteriores: Resultados a largo plazo

et al. 2005

View full text Add to dashboard Cite

Resumen• Propósito: evaluar la eficacia y la seguridad a largo plazo de la braquiterapia con hilos extraesclerales de iridio-192 en melanoma uveal posterior.• Material y métodos: serie retrospectiva no controlada de 241 pacientes tratados entre enero de 1983 y junio de 2005 en un hospital de referencia nacional.• Resultados: seguimiento medio de 5,4 años, con 17% de pérdidas de seguimiento, probabilidades de supervivencia libre de enfermedad a 5 y 10 años del 77% (I.C. del 95%: 72; 83) y del 64% (I.C. del 95%: 56; 73), de conservar el ojo a 5 y 10 años del 74% (I.C. del 95 %: 68; 80) y del 63% (I.C. del 95%: 55; 71), de conservan una agudeza visual de al menos 0,05 a 1, 5 y 10 años del 64% (I.C. del 95%: 57; 71), del 28% (I.C. del 95%: 21; 35) y del 15% (I.C. del 95%: 8; 23). La probabilidad a 5 años de enucleación por complicaciones fue del 11% (I.C. del 95%: 6; 16) en melanomas de coroides y del 58% (I.C. del 95%: 27; 89) en melanomas de cuerpo ciliar (p < 0.001).• Conclusiones: la braquiterapia con hilos de iridio-192 consigue un control de la enfermedad similar a las placas de iodo-125; sin embargo, la incidencia de enucleación por complicaciones de la radiación es aparentemente mayor en la técnica con iridio-192, especialmente en melanomas de cuerpo ciliar. Palabras clave:Neoplasias uveales. Melanoma. Braquiterapia. Radioisótopos de iridio. Probabilidad de supervivencia. Supervivencia libre de enfermedad Oncología, 2005; 28 (9):415-425 • Conclusion: wire brachytherapy achieves a disease control similar to that obtained with iodine-125 plaques, but the rate of complications requiring a secondary enucleation seems to be greater with the iridium-192 procedure, especially in ciliary body melanomas.

show abstract

“…Indeed, the literature states that, for uveal melanomas, the extremity exposure would allow a surgeon to annually perform only 50 to 100 cases of plaque brachytherapy. 21 We undertook this study to determine the surgeon's hand dose for verification that staff radiation doses are below regulatory limits.…”

mentioning

confidence: 99%

Radiation Dose to the Surgeon During Plaque Brachytherapy

Classic¹,

Furutani²,

Stafford³

et al. 2012

Retina

View full text Add to dashboard Cite

show abstract

Determination of surgeon’s absorbed dose in iodine 125 and ruthenium 106 ophthalmic plaque surgery

Cited by 22 publications

References 8 publications

Trends in Radiation Practices for Female Ocular Oncologists in North America: A Collaborative Study of the International Society of Ocular Oncology

Trends in Radiation Practices for Female Ocular Oncologists in North America: A Collaborative Study of the International Society of Ocular Oncology

Braquiterapia con hilos extraesclerales de iridio-192 en melanomas uveales posteriores: Resultados a largo plazo

Radiation Dose to the Surgeon During Plaque Brachytherapy

Contact Info

Product

Resources

About